H107e/CAF10b / Statens Serum Institut - LARVOL DELTA

nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: Statens Serum Institut | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Statens Serum Institut | Trial completion date: May 2026 ➔ Nov 2026 | Trial primary completion date: May 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Statens Serum Institut | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IFNG • IL17A

nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107/CAF®10b (clinicaltrials.gov) - P1b | N=140 | Not yet recruiting | Sponsor: Statens Serum Institut

New P1 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL17A